## RECEIVED JUL 2 4 2001

TECH CENTER 1600/2900

## SEQUENCE LISTING

<110> Harris, Curtis C

Nagashima, Makoto Government of United States as represented by the Secretary of the

Department of Health and Human Services

<120> New Tumor Suppressor Gene P33ING2

<130> 015280-376100US

<140> US 09/513,365

<141> 2000-02-25

<150> US 60/121,891

<151> 1999-02-26

<160> 10

<170> PatentIn Ver. 2.1

<210> 1

<211> 280

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: p33ING2 polypeptide sequence

<400> 1

Met Leu Gly Gln Gln Gln Gln Leu Tyr Ser Ser Ala Ala Leu Leu 10

Thr Gly Glu Arg Ser Arg Leu Leu Thr Cys Tyr Val Gln Asp Tyr Leu

Glu Cys Val Glu Ser Leu Pro His Asp Met Gln Arg Asn Val Ser Val 40

Leu Arg Glu Leu Asp Asn Lys Tyr Gln Glu Thr Leu Lys Glu Ile Asp 50

Asp Val Tyr Glu Lys Tyr Lys Lys Glu Asp Asp Leu Asn Gln Lys Lys

Arg Leu Gln Gln Leu Leu Gln Arg Ala Leu Ile Asn Ser Gln Glu Leu

Gly Asp Glu Lys Ile Gln Ile Val Thr Gln Met Leu Glu Leu Val Glu 105

Asn Arg Ala Arg Gln Met Glu Leu His Ser Gln Cys Phe Gln Asp Pro

Ala Glu Ser Glu Arg Ala Ser Asp Lys Ala Lys Met Asp Ser Ser Gln

Pro Glu Arg Ser Ser Arg Arg Pro Arg Arg Gln Arg Thr Ser Glu Ser 155 160 Arg Asp Leu Cys His Met Ala Asn Gly Ile Glu Asp Cys Asp Asp Gln 170 175 Pro Pro Lys Glu Lys Lys Ser Lys Ser Ala Lys Lys Lys Arg Ser 185 Lys Ala Lys Gln Glu Arg Glu Ala Ser Pro Val Glu Phe Ala Ile Asp 200 Pro Asn Glu Pro Thr Tyr Cys Leu Cys Asn Gln Val Ser Tyr Gly Glu 210 Met Ile Gly Cys Asp Asn Glu Gln Cys Pro Ile Glu Trp Phe His Phe 230 235 Ser Cys Val Ser Leu Thr Tyr Lys Pro Lys Gly Lys Trp Tyr Cys Pro 250 Lys Cys Arg Gly Asp Asn Glu Lys Thr Met Asp Lys Ser Thr Glu Lys 265 Thr Lys Lys Asp Arg Arg Ser Arg 275 <210> 2 <211> 1080 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: p33ING2 nucleic acid sequence (GenBank Accession No. AF05053537)

gcggccgcgg ccggtgcatg tgcggctgct ggatgcggag gcggcggcga cggcgcggat 60 cggcaggatg ttagggcagc agcagcagca actgtactcg tcggctgcgc tcctgaccgg 120 ggagcggagc cggctgctca cctgctacgt gcaggactac cttgagtgcg tggagtcgct 180 qccccacgac atgcagagga acgtgtctgt gctgcgagag ctggacaaca aatatcaaga 240 aacgttaaag gaaattgatg atgtctacga aaaatataag aaagaagatg atttaaacca 300 gaagaaacgt ctacagcagc ttctccagag agcactaatt aatagtcaag aattgggaga 360 tgaaaaaata cagattgtta cacaaatgct cgaattggtg gaaaatcggg caagacaaat 420 ggagttacac tcacagtgtt tccaagatcc tgctgaaagt gaacgagcct cagataaagc 480 aaagatggat tccagccaac cagaaagatc ttcaagaaga ccccgcaggc agcggaccag 540 tgaaagccgt gatttatgtc acatggcaaa tgggattgaa gactgtgatg atcagccacc 600 taaagaaaag aaatccaagt cagcaaagaa aaagaaacgc tccaaggcca agcaggaaag 660 ggaagettea cetgttgagt ttgcaataga teetaatgaa eetacataet gettatgcaa 720 ccaagtgtct tatggggaga tgataggatg tgacaatgaa cagtgtccaa ttgaatggtt 780 tcacttttca tgtgtttcac ttacctataa accaaagggg aaatggtatt gcccaaagtg 840 caggggagat aatgagaaaa caatggacaa aagtactgaa aagacaaaaa aggatagaag 900 atcgaggtag taaaggccat ccacatttta aagggttatt tgtcttttat ataattcgtt 960 tgctttcaga aaatgtttta gggtaaatgc ataagactat gcaataattt ttaatcatta 1020 

```
<210> 3
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Degenerate
     primer used to isolate p33ING2 nucleic acids
<400> 3
Met Leu Gly Gln Gln Gln
<210> 4
<211> 7
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Degenerate
      primer used to isolate p33ING2 nucleic acid
<400> 4
Lys Lys Asp Arg Arg Ser Arg
<210> 5
<211> 20
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: peptide 7-26
      of p33ING2 (KMP1)
Gln Gln Leu Tyr Ser Ser Ala Ala Leu Leu Thr Gly Glu Arg Ser Arg
                 5
                                     10
 1
Leu Leu Thr Cys
<210> 6
<211> 280
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: missense
     p33ING2 sequence - Arg 153 to Ser
Met Leu Gly Gln Gln Gln Gln Leu Tyr Ser Ser Ala Ala Leu Leu
                                     10
Thr Gly Glu Arg Ser Arg Leu Leu Thr Cys Tyr Val Gln Asp Tyr Leu
                                 25
                                                      30
             20
```

Glu Cys Val Glu Ser Leu Pro His Asp Met Gln Arg Asn Val Ser Val Leu Arg Glu Leu Asp Asn Lys Tyr Gln Glu Thr Leu Lys Glu Ile Asp Asp Val Tyr Glu Lys Tyr Lys Lys Glu Asp Asp Leu Asn Gln Lys Lys Arg Leu Gln Gln Leu Leu Gln Arg Ala Leu Ile Asn Ser Gln Glu Leu 90 Gly Asp Glu Lys Ile Gln Ile Val Thr Gln Met Leu Glu Leu Val Glu Asn Arg Ala Arg Gln Met Glu Leu His Ser Gln Cys Phe Gln Asp Pro Ala Glu Ser Glu Arg Ala Ser Asp Lys Ala Lys Met Asp Ser Ser Gln 135 Pro Glu Arg Ser Ser Arg Arg Pro Ser Arg Gln Arg Thr Ser Glu Ser Arg Asp Leu Cys His Met Ala Asn Gly Ile Glu Asp Cys Asp Asp Gln 165 Pro Pro Lys Glu Lys Lys Ser Lys Ser Ala Lys Lys Lys Lys Arg Ser 185 190 Lys Ala Lys Gln Glu Arg Glu Ala Ser Pro Val Glu Phe Ala Ile Asp Pro Asn Glu Pro Thr Tyr Cys Leu Cys Asn Gln Val Ser Tyr Gly Glu Met Ile Gly Cys Asp Asn Glu Gln Cys Pro Ile Glu Trp Phe His Phe Ser Cys Val Ser Leu Thr Tyr Lys Pro Lys Gly Lys Trp Tyr Cys Pro . 250 Lys Cys Arg Gly Asp Asn Glu Lys Thr Met Asp Lys Ser Thr Glu Lys 265 260

Thr Lys Lys Asp Arg Arg Ser Arg

```
<210> 7
<211> 423
<212> DNA
<213> Homo sapiens
<220>
<223> p 33ING2 genomic DNA sequence (exon 1/intron)
      GenBank Accession No. HSING2S1
<221> exon
<222> (1)..(239)
<221> intron
<222> (240)..(>423)
<400> 7
geggeegegg ceggtgeatg tgeggetget ggatgeggag geggeggega eggegggat 60
cggcaggatg ttagggcagc agcagcagca actgtactcg tcggctgcgc tcctgaccgg 120
ggagcggagc cggctgctca cctgctacgt gcaggactac cttgagtgcg tggagtcgct 180
gcccacgac atgcagagga acgtgtctgt gctgcgagag ctggacaaca aatatcaagg 240
taggggccgc ggggctgccg gcctcgggag ccggtggcgg ggagcctgtc cgggggagtg 300
ccaccttccc tttctcccgt gacagtctcc ccgagcgcac cgagggtctg ccgagcggga 360
ctgggaggac tggagaccgg gttggcggcc ctccgtggcc ccgcggtggg cgagtgaagg 420
<210> 8
<211> 279
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: p33ING1
Met Leu Ser Pro Ala Asn Gly Glu Gln Leu His Leu Val Asn Tyr Val
Glu Asp Tyr Leu Asp Ser Ile Glu Ser Leu Pro Phe Asp Leu Gln Arg
             20
Asn Val Ser Leu Met Arg Glu Ile Asp Ala Lys Tyr Gln Glu Ile Leu
                             40
Lys Glu Leu Asp Glu Cys Tyr Glu Arg Phe Ser Arg Glu Thr Asp Gly
Ala Gln Lys Arg Arg Met Leu His Cys Val Gln Arg Ala Leu Ile Arg
Ser Gln Glu Leu Gly Asp Glu Lys Ile Gln Ile Val Ser Gln Met Val
                 85
Glu Leu Val Glu Asn Arg Thr Arg Gln Val Asp Ser His Val Glu Leu
                                105
Phe Glu Ala Gln Gln Glu Leu Gly Asp Thr Ala Gly Asn Ser Gly Lys
        115
Ala Gly Ala Asp Arg Pro Lys Gly Glu Ala Ala Gln Ala Asp Lys
                        135
                                            140
    130
```

Pro Asn Ser Lys Arg Ser Arg Arg Gln Arg Asn Asn Glu Asn Arg Glu 150 Asn Ala Ser Ser Asn His Asp His Asp Asp Gly Ala Ser Gly Thr Pro 165 170 Lys Glu Lys Lys Ala Lys Thr Ser Lys Lys Lys Arg Ser Lys Ala 185 Lys Ala Glu Arg Glu Ala Ser Pro Ala Asp Leu Pro Ile Asp Pro Asn 200 Glu Pro Thr Tyr Cys Leu Cys Asn Gln Val Ser Tyr Gly Glu Met Ile 215 Gly Cys Asp Asn Asp Glu Cys Pro Ile Glu Trp Phe His Phe Ser Cys 235 Val Gly Leu Asn His Lys Pro Lys Gly Lys Trp Tyr Cys Pro Lys Cys 245 Arg Gly Glu Asn Glu Lys Thr Met Asp Lys Ala Leu Glu Lys Ser Lys 265 Lys Glu Arg Ala Tyr Asn Arg 275 <210> 9 <211> 279 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: peptide 1-17 and C of p33ING1 (KMP2) <400> 9 Met Leu Ser Pro Ala Asn Gly Glu Gln Leu His Leu Val Asn Tyr Val 10 Glu Asp Tyr Leu Asp Ser Ile Glu Ser Leu Pro Phe Asp Leu Gln Arg Asn Val Ser Leu Met Arg Glu Ile Asp Ala Lys Tyr Gln Glu Ile Leu Lys Glu Leu Asp Glu Cys Tyr Glu Arg Phe Ser Arg Glu Thr Asp Gly 50 Ala Gln Lys Arg Arg Met Leu His Cys Val Gln Arg Ala Leu Ile Arg Ser Gln Glu Leu Gly Asp Glu Lys Ile Gln Ile Val Ser Gln Met Val 90 Glu Leu Val Glu Asn Arg Thr Arg Gln Val Asp Ser His Val Glu Leu

105

100

- Phe Glu Ala Gln Glu Leu Gly Asp Thr Ala Gly Asn Ser Gly Lys 115 120 125
- Ala Gly Ala Asp Arg Pro Lys Gly Glu Ala Ala Gln Ala Asp Lys
  130 135 140
- Pro Asn Ser Lys Arg Ser Arg Arg Gln Arg Asn Asn Glu Asn Arg Glu 145 150 155 160
- Asn Ala Ser Ser Asn His Asp His Asp Gly Ala Ser Gly Thr Pro 165 170 175
- Lys Glu Lys Lys Ala Lys Thr Ser Lys Lys Lys Lys Arg Ser Lys Ala 180 185 190
- Lys Ala Glu Arg Glu Ala Ser Pro Ala Asp Leu Pro Ile Asp Pro Asn 195 200 205
- Glu Pro Thr Tyr Cys Leu Cys Asn Gln Val Ser Tyr Gly Glu Met Ile 210 215 220
- Gly Cys Asp Asn Asp Glu Cys Pro Ile Glu Trp Phe His Phe Ser Cys 225 230 235 240
- Val Gly Leu Asn His Lys Pro Lys Gly Lys Trp Tyr Cys Pro Lys Cys 245 250 255
- Arg Gly Glu Asn Glu Lys Thr Met Asp Lys Ala Leu Glu Lys Ser Lys 260 265 270
- Lys Glu Arg Ala Tyr Asn Arg 275

```
<210> 10
<211> 974
<212> DNA
<213> Homo sapiens
<220>
<223> p33ING2 genomic DNA sequence (Exon 2/intron)
      GenBank Accession No. HSING2S2
<221> intron
<222> (<1)..(123)
<221> exon
<222> (124)..(938)
<400> 10
ccaaagagga gtatggtttc atggtttgag ttctaatttc aattctgtaa aaaataacta 60
ccttggaaat gttgtgtctg ctaacacatg ataacgttct catttttctt ttccttttt 120
tagaaacgtt aaaggaaatt gatgatgtct acgaaaaata taagaaagaa gatgatttaa 180
accagaagaa acgtctacag cagcttctcc agagagcact aattaatagt caagaattgg 240
qaqatqaaaa aatacagatt gttacacaaa tgctcgaatt ggtggaaaat cgggcaagac 300
aaatggagtt acactcacag tgtttccaag atcctgctga aagtgaacga gcctcagata 360
aagcaaagat ggattccagc caaccagaaa gatcttcaag aagaccccgc aggcagcgga 420
ccagtgaaag ccgtgattta tgtcacatgg caaatgggat tgaagactgt gatgatcagc 480
cacctaaaga aaagaaatcc aagtcagcaa agaaaaagaa acgctccaag gccaagcagg 540
aaagggaagc ttcacctgtt gagtttgcaa tagatcctaa tgaacctaca tactgcttat 600
gcaaccaagt gtcttatggg gagatgatag gatgtgacaa tgaacagtgt ccaattgaat 660
ggtttcactt ttcatgtgtt tcacttacct ataaaccaaa ggggaaatgg tattgcccaa 720
agtgcagggg agataatgag aaaacaatgg acaaaagtac tgaaaagaca aaaaaggata 780
gaagatcgag gtagtaaagg ccatccacat tttaaagggt tatttgtctt ttatataatt 840
cgtttgcttt cagaaaatgt tttagggtaa atgcataaga ctatgcaata atttttaatc 900
attagtatta atggtgtatt aaaagttgtt gtactttgtc tgtgacctta attttctgca 960
ctgagttacc aaat
```